Market Valuation & Earnings Multiples
Market capitalization, P/E ratios, and enterprise value
Market Cap439.64M
Enterprise Value806.34M
Trailing P/E8.36
EBS
(NYSE)Emergent BioSolutions Inc.
$8.39-- (--)
Loading... - Market loading
Emergent BioSolutions (EBS) Key Statistics & Financial Metrics
Complete stock analysis with 40+ metrics: valuation ratios, profitability margins, financial health indicators, and dividend data.
Stock Valuation Metrics
Market value, earnings multiples, and pricing ratios
Price-Based Ratios
Valuation ratios based on stock price
Price/Sales (ttm)0.62
Forward Price/Sales0.89
Price/Book (mrq)0.84
Price/Tangible Book (mrq)5.11
Price/FCF (ttm)2.80
Price/OCF (ttm)2.58
Enterprise Value Ratios
EV-based valuation multiples
EV/Revenue1.14
EV/Earnings15.33
EV/EBITDA3.39
EV/EBIT5.67
EV/FCF5.14
Stock Price
Current price, 52-week range, and moving averages
Current Price$8.39
1-Day Change6.88%
52-Week High$14.06
52-Week Low$4.02
52-Week Change88.96%
YTD Change-32.93%
1-Year Change78.89%
50-Day MA$9.53
200-Day MA$9.48
Avg Volume (30 day)635.41K
Share Statistics
Outstanding shares, float, and per-share metrics
Shares Outstanding52.40M
Book Value per Share$9.97
Net Cash per Share$3.92
FCF per Share$2.99
Analyst Price Targets & Consensus
Wall Street analyst ratings and 12-month price targets (90 days)
Price Target$12.00
Target Upside/Downside43.03%
Analyst ConsensusBuy
Analyst Count1
Profitability & Financial Performance
Profit margins, return metrics, and earnings analysis
Profit Margins
Profitability margins across income statement
Gross Margin53.74%
EBITDA Margin (ttm)33.74%
EBIT Margin (ttm)20.15%
Operating Margin (ttm)15.92%
Pretax Margin (ttm)11.74%
Profit Margin (ttm)7.46%
FCF Margin (ttm)22.23%
Return on Investment Metrics
ROE, ROA, ROIC, and capital efficiency ratios
Return on Equity (ttm)10.07%
Return on Assets (ttm)3.99%
Return on Invested Capital (ttm)10.15%
Return on Capital Employed (ttm)11.98%
Income Statement (TTM)
Trailing twelve months revenue and earnings
Revenue705.20M
Gross Profit379.00M
Operating Income112.30M
Pretax Income82.80M
Net Income52.60M
EBITDA237.90M
EBIT142.10M
Diluted EPS$1.00
Cash Flow (TTM)
Operating cash flow and free cash flow metrics
Operating Cash Flow170.60M
Capital Expenditures13.80M
Free Cash Flow156.80M
Growth Rates (YoY)
Year-over-year growth metrics
Revenue Growth-28.65%
Financial Health & Dividends
Balance sheet analysis, debt ratios, and dividend metrics
Assets & Cash
Total assets and cash positions
Total Assets (mrq)1.32B
Cash & Securities (mrq)205.40M
Net Cash (mrq)205.40M
Net Cash per Share$3.92
Debt & Liabilities
Liabilities, debt, equity, and working capital
Total Debt (mrq)572.10M
Working Capital (mrq)530.30M
Total Equity (mrq)522.60M
Book Value per Share$9.97
Liquidity & Leverage
Liquidity, leverage, and debt coverage ratios
Current Ratio (mrq)5.01
Quick Ratio (mrq)2.41
Debt/Equity (mrq)1.09
Debt/EBITDA (ttm)2.40
Debt/FCF (ttm)3.65
Dividend History & Payout Analysis
Dividend yield, payout ratios, and growth metrics
Dividend per Share (TTM)$0.00
Dividend Yield0.00%
Payout Ratio (Earnings)0.00%
Ex-Dividend DateAug 1, 2016
Pay DateAug 1, 2016
Yield Metrics
Earnings, FCF, buyback, and shareholder yields
Earnings Yield11.96%
FCF Yield35.67%
Buyback Yield5.66%
Total Shareholder Yield5.66%
Financial Health Scores
Risk assessment and quality metrics
Altman Z-Score1.53
Piotroski F-Score8/9
Fair Value & Intrinsic Value
Lynch fair value, Graham number, and valuation models
Graham Number$15.01
Graham Upside/Downside78.88%
Frequently Asked Questions About Emergent BioSolutions Statistics
What are the key financial metrics for EBS?
Emergent BioSolutions Inc. (EBS) statistics include 40+ financial metrics organized into valuation ratios (P/E, P/S, P/B, PEG), profitability margins (gross, operating, net), return metrics (ROE, ROA, ROIC), and financial health indicators. These are updated regularly based on the latest filings and market data.
What is EBS's valuation analysis?
The valuation section covers market capitalization, earnings multiples like trailing and forward P/E, price-based ratios (P/S, P/B, Price/FCF), and enterprise value ratios (EV/EBITDA, EV/Revenue, EV/FCF). Compare these against sector averages to assess whether Emergent BioSolutions is overvalued or undervalued.
How do I read EBS's profitability ratios?
Emergent BioSolutions's profitability is measured through profit margins (gross, EBITDA, operating, net) and return metrics (ROE, ROA, ROIC, ROCE). Higher margins indicate better cost control, while higher returns show efficient capital deployment. The income statement and cash flow sections provide the underlying revenue and earnings data.
What do EBS's debt ratios indicate?
The financial health section shows Emergent BioSolutions's leverage through debt-to-equity, debt-to-assets, debt-to-EBITDA, and debt-to-FCF ratios, plus liquidity via the current and quick ratios. Lower debt ratios and higher liquidity ratios generally indicate stronger financial stability and lower default risk.
What is EBS's dividend analysis?
The dividend section covers Emergent BioSolutions's dividend yield, payout ratios (earnings-based and FCF-based), year-over-year dividend growth, years of consecutive growth, ex-dividend and pay dates, and payment frequency. The yield metrics section also includes earnings yield, FCF yield, buyback yield, and total shareholder yield.